Chemotherapy Induced Nausea and Vomiting – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Chemotherapy Induced Nausea and Vomiting – Pipeline Review, H2 2017’, provides an overview of the Chemotherapy Induced Nausea and Vomiting pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Chemotherapy Induced Nausea and Vomiting, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Chemotherapy Induced Nausea and Vomiting and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Chemotherapy Induced Nausea and Vomiting

The report reviews pipeline therapeutics for Chemotherapy Induced Nausea and Vomiting by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Chemotherapy Induced Nausea and Vomiting therapeutics and enlists all their major and minor projects

The report assesses Chemotherapy Induced Nausea and Vomiting therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Chemotherapy Induced Nausea and Vomiting

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Chemotherapy Induced Nausea and Vomiting

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Chemotherapy Induced Nausea and Vomiting pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Acacia Pharma Ltd

Aphios Corp

Astellas Pharma Inc

Athenex Inc

Camurus AB

Daewoong Pharmaceutical Co Ltd

Heron Therapeutics Inc

Insys Therapeutics Inc

Kyowa Hakko Kirin Co Ltd

MannKind Corp

Medlab Clinical Ltd

N4 Pharma Plc

Nanoform Cardiovascular Therapeutics Ltd

Nemus Bioscience Inc

RedHill Biopharma Ltd

Serina Therapeutics Inc

SoluBest Ltd

Suda Ltd

Tesaro Inc

Therapix Biosciences Ltd

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Chemotherapy Induced Nausea and Vomiting - Overview 6

Chemotherapy Induced Nausea and Vomiting - Therapeutics Development 7

Pipeline Overview 7

Pipeline by Companies 8

Products under Development by Companies 11

Chemotherapy Induced Nausea and Vomiting - Therapeutics Assessment 13

Assessment by Target 13

Assessment by Mechanism of Action 15

Assessment by Route of Administration 17

Assessment by Molecule Type 19

Chemotherapy Induced Nausea and Vomiting - Companies Involved in Therapeutics Development 20

Acacia Pharma Ltd 20

Aphios Corp 20

Astellas Pharma Inc 21

Athenex Inc 21

Camurus AB 22

Daewoong Pharmaceutical Co Ltd 22

Heron Therapeutics Inc 23

Insys Therapeutics Inc 23

Kyowa Hakko Kirin Co Ltd 24

MannKind Corp 24

Medlab Clinical Ltd 25

N4 Pharma Plc 25

Nanoform Cardiovascular Therapeutics Ltd 26

Nemus Bioscience Inc 26

RedHill Biopharma Ltd 27

Serina Therapeutics Inc 27

SoluBest Ltd 28

Suda Ltd 28

Tesaro Inc 29

Therapix Biosciences Ltd 29

Chemotherapy Induced Nausea and Vomiting - Drug Profiles 30

(netupitant + palonosetron hydrochloride) - Drug Profile 30

(palonosetron hydrochloride + Pro-netupitant) - Drug Profile 34

APD-403 - Drug Profile 35

aprepitant - Drug Profile 37

aprepitant - Drug Profile 38

aprepitant - Drug Profile 39

aprepitant - Drug Profile 40

aprepitant - Drug Profile 41

aprepitant - Drug Profile 42

Cannabis CINV - Drug Profile 43

dexamethasone - Drug Profile 44

dronabinol - Drug Profile 45

dronabinol - Drug Profile 46

FK-886 - Drug Profile 47

fosnetupitant - Drug Profile 49

granisetron hydrochloride - Drug Profile 50

granisetron hydrochloride - Drug Profile 51

granisetron hydrochloride - Drug Profile 52

granisetron hydrochloride ER - Drug Profile 53

LPI-1504 - Drug Profile 55

LPI-1505 - Drug Profile 56

NB-1222 - Drug Profile 57

NB-2111 - Drug Profile 58

netupitant - Drug Profile 59

ondansetron hydrochloride - Drug Profile 60

ondansetron hydrochloride - Drug Profile 62

ondansetron hydrochloride - Drug Profile 63

ondansetron hydrochloride - Drug Profile 64

ondansetron hydrochloride CR - Drug Profile 65

palmidrol - Drug Profile 72

palonosetron hydrochloride - Drug Profile 73

rolapitant hydrochloride - Drug Profile 74

SER-232 - Drug Profile 80

Zindol - Drug Profile 81

Chemotherapy Induced Nausea and Vomiting - Dormant Projects 82

Chemotherapy Induced Nausea and Vomiting - Discontinued Products 83

Chemotherapy Induced Nausea and Vomiting - Product Development Milestones 84

Featured News & Press Releases 84

Appendix 94

Methodology 94

Coverage 94

Secondary Research 94

Primary Research 94

Expert Panel Validation 94

Contact Us 94

Disclaimer 95

List of Tables

List of Tables

Number of Products under Development for Chemotherapy Induced Nausea and Vomiting, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Chemotherapy Induced Nausea and Vomiting – Pipeline by Acacia Pharma Ltd, H2 2017

Chemotherapy Induced Nausea and Vomiting – Pipeline by Aphios Corp, H2 2017

Chemotherapy Induced Nausea and Vomiting – Pipeline by Astellas Pharma Inc, H2 2017

Chemotherapy Induced Nausea and Vomiting – Pipeline by Athenex Inc, H2 2017

Chemotherapy Induced Nausea and Vomiting – Pipeline by Camurus AB, H2 2017

Chemotherapy Induced Nausea and Vomiting – Pipeline by Daewoong Pharmaceutical Co Ltd, H2 2017

Chemotherapy Induced Nausea and Vomiting – Pipeline by Heron Therapeutics Inc, H2 2017

Chemotherapy Induced Nausea and Vomiting – Pipeline by Insys Therapeutics Inc, H2 2017

Chemotherapy Induced Nausea and Vomiting – Pipeline by Kyowa Hakko Kirin Co Ltd, H2 2017

Chemotherapy Induced Nausea and Vomiting – Pipeline by MannKind Corp, H2 2017

Chemotherapy Induced Nausea and Vomiting – Pipeline by Medlab Clinical Ltd, H2 2017

Chemotherapy Induced Nausea and Vomiting – Pipeline by N4 Pharma Plc, H2 2017

Chemotherapy Induced Nausea and Vomiting – Pipeline by Nanoform Cardiovascular Therapeutics Ltd, H2 2017

Chemotherapy Induced Nausea and Vomiting – Pipeline by Nemus Bioscience Inc, H2 2017

Chemotherapy Induced Nausea and Vomiting – Pipeline by RedHill Biopharma Ltd, H2 2017

Chemotherapy Induced Nausea and Vomiting – Pipeline by Serina Therapeutics Inc, H2 2017

Chemotherapy Induced Nausea and Vomiting – Pipeline by SoluBest Ltd, H2 2017

Chemotherapy Induced Nausea and Vomiting – Pipeline by Suda Ltd, H2 2017

Chemotherapy Induced Nausea and Vomiting – Pipeline by Tesaro Inc, H2 2017

Chemotherapy Induced Nausea and Vomiting – Pipeline by Therapix Biosciences Ltd, H2 2017

Chemotherapy Induced Nausea and Vomiting – Dormant Projects, H2 2017

Chemotherapy Induced Nausea and Vomiting – Discontinued Products, H2 2017

List of Figures

List of Figures

Number of Products under Development for Chemotherapy Induced Nausea and Vomiting, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products by Targets, H2 2017

Number of Products by Stage and Targets, H2 2017

Number of Products by Mechanism of Actions, H2 2017

Number of Products by Stage and Mechanism of Actions, H2 2017

Number of Products by Top 10 Routes of Administration, H2 2017

Number of Products by Stage and Top 10 Routes of Administration, H2 2017

Number of Products by Stage and Molecule Types, H2 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports